2022

A tender for the execution of engineering works at ITMO Highpark went to the architectural bureau Studio 44, which expects to complete the design for the second and third stages by late 2023. Studio 44 will receive a tender of 337 million…

In 2022, ITMO launched its first accelerator for foodtech projects, where participants learned to manage teams, choose the most appropriate markets for their products, and attract investments. Read on to learn more about the projects that…

ITMO’s Research Center “Strong AI in Industry” has launched an open-source mentorship program that will allow students to work at the university, helping research groups develop open-source frameworks and libraries. Read on to learn about…

A new version of the ChatGPT chatbot, belonging to the acclaimed GPT-3 family of language models, was published in late November. The developers made significant updates to the chatbot, adding a plethora of new features – for instance,…

With ITMO’s Mega Contest, you can enter the university’s Master’s programs without entrance exams. Having launched in the 2021-2022 academic year, the contest is now in its second season. Here’s all you need to know about it. What is the…

Last year marked the launch of Priority 2030, a national program aimed at comprehensive development of the Russian higher education system. According to a recent performance review conducted by the Russian Ministry of Science and Higher…

Russian figure skater Petr Gumennik, a first-year student at ITMO’s Faculty of Software Engineering and Computer Systems, has come second to Evgeni Semenenko in the 2023 Russian Figure Skating Championships, scoring 295.07 points.Petr…

Pfizer Inc. (NYSE: PFE) today announced that the U.S. Food and Drug Administration (FDA) accepted for priority review a Biologics License Application (BLA) for its respiratory syncytial virus (RSV) vaccine candidate, PF-06928316 or…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced the U.S. Food and Drug Administration (FDA) granted Emergency Use Authorization (EUA) of their Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine as the third 3-µg…

Pfizer Inc. (NYSE:PFE) today announced 10.4 month follow-up data from the pivotal Phase 2 MagnetisMM-3 clinical trial suggesting elranatamab, a B-cell maturation antigen (BCMA)-CD3-targeted bispecific antibody (BsAb), is efficacious and…